OV-mOX40L

**OV-mOX40L** is a genetically engineered oncolytic virus based on herpes simplex virus type 1 (HSV-1) that expresses murine OX40 ligand (OX40L). It is designed to combine the direct tumor cell killing of oncolytic virotherapy with the immunostimulatory action of OX40L, aiming to modulate the tumor microenvironment and enhance anti-tumor immune responses. OV-mOX40L boosts infiltration of CD4+ and CD8+ T cells, reduces regulatory T cells, reprograms macrophages and neutrophils towards a pro-inflammatory and anti-tumor phenotype, and decreases myofibroblastic cancer-associated fibroblasts. In preclinical studies in mouse models of pancreatic ductal adenocarcinoma (PDAC), it significantly prolonged survival, especially when combined with anti-IL6 or anti-PD-1 antibodies. The mechanism relies on the activation and proliferation of T cells via OX40-OX40L signaling, remodeling of the stromal matrix, and enhanced immunogenic cell death of tumor cells[1][4].

Other names

HSV-1-mOX40LHSV1-mOX40LHSV 1-mOX40L